Skip to main content

Cell Therapeutics' FDA Panel: Live Blog

Read columnist Adam Feuerstein's live blog of the Cell Therapeutics' FDA Panel held on Monday.

Our biotech columnist live-blogged the outside panel of cancer experts convened by the FDA reviews Cell Therapeutics' lymphoma drug pixantrone on Monday; read on to review the action.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.

Scroll to Continue

TheStreet Recommends